Meritain Health policies

Search Meritain Health's public medical, payment and drug policies by CPT or HCPCS code, keyword or policy number, with links to the payer's own documents. Links open the payer's own document; check its current version before relying on it.

38 policies name 38206, those listing the fewest codes first. A policy that names a code may also list it as excluded.

Meritain Health policies
PolicyDetailsCodesSource
0163-Transmyocardial and Endovascular Laser Revascularization0163 · Commercial5Original policy ↗
Hematopoietic Cell Transplantation for Breast Cancer0507 · Commercial5Original policy ↗
0740-Pralatrexate0740 · Commercial7Original policy ↗
Hematopoietic Cell Transplantation for Testicular Cancer0617 · Commercial8Original policy ↗
Hematopoietic Cell Transplantation for Ovarian Cancer0635 · Commercial9Original policy ↗
0674-Hematopoietic Cell Transplantation for Chronic Myelogenous Leukemia0674 · Commercial11Original policy ↗
0871-Hematopoietic Cell Transplantation for Inherited Metabolic Disorders and Genetic Diseases0871 · Commercial13Original policy ↗
Motixafortide (Aphexda)1046 · Commercial13Original policy ↗
0836-Hematopoietic Cell Transplantation for Myelodysplastic Syndrome0836 · Commercial14Original policy ↗
0779-Plerixafor0779 · Commercial15Original policy ↗
0811-Hematopoietic Cell Transplantation for Solid Tumors in Adults0811 · Commercial15Original policy ↗
Hematopoietic Cell Transplantation for Non-Hodgkin's Lymphoma0494 · Commercial16Original policy ↗
Hematopoietic Cell Transplantation for Selected Leukemias0640 · Commercial17Original policy ↗
Betibeglogene Autotemcel (Zynteglo)1016 · Commercial18Original policy ↗
Hematopoietic Cell Transplantation for Autoimmune Diseases and Miscellaneous Indications0606 · Commercial19Original policy ↗
Hematopoietic Cell Transplantation for Multiple Myeloma0497 · Commercial21Original policy ↗
1097-Etuvetidigene Autotemcel (Waskyra)1097 · Commercial22Original policy ↗
Hematopoietic Cell Transplantation for Hodgkin's Disease0495 · Commercial23Original policy ↗
1099-Narsoplimab-wuug (Yartemlea)1099 · Commercial25Original policy ↗
Hematopoietic Cell Transplantation for Selected Childhood Solid Tumors0496 · Commercial25Original policy ↗
0852-Neurogenic Bladder: Selected Treatments0852 · Commercial27Original policy ↗
Hematopoietic Cell Transplantation for Thalassemia Major and Sickle Cell Anemia0626 · Commercial27Original policy ↗
Stem Cells for Hematopoietic Cell Transplant0190 · Commercial29Original policy ↗
1058-Atidarsagene Autotemcel (Lenmeldy)1058 · Commercial30Original policy ↗
Pegzilarginase-nbln (Loargys)1101 · Commercial35Original policy ↗
0904-Daratumumab (Darzalex) and Daratumumab and Hyaluronidase-fihj (Darzalex Faspro)0904 · Commercial39Original policy ↗
0789-Acute Ischemic Stroke: Treatments0789 · Commercial40Original policy ↗
0784-Blood and Adipose Tissue Derived Products for Selected Indications0784 · Commercial47Original policy ↗
0823-Brentuximab Vedotin (Adcetris)0823 · Commercial47Original policy ↗
1102-Marnetegragene Autotemcel (Kresladi)1102 · Commercial48Original policy ↗
Growth Hormone (GH) and Growth Hormone Antagonists0170 · Commercial52Original policy ↗
Fecal Incontinence0611 · Commercial62Original policy ↗
0673-Knee Arthroscopy / Osteoarthritis of the Knee0673 · Commercial67Original policy ↗
Alopecia Areata0423 · Commercial72Original policy ↗
Ventricular Assist Devices0654 · Commercial100Original policy ↗
Multiple Sclerosis0264 · Commercial126Original policy ↗
Temporomandibular Disorders0028 · Commercial197Original policy ↗
0648-Autism Spectrum Disorders0648 · Commercial284Original policy ↗

Back to Meritain Health

Disclaimer

The information provided on this page is for general informational purposes only and does not constitute billing, coding, or reimbursement advice. Nothing on this page should be relied upon as a substitute for clinician assessment, professional billing guidance, or as a definitive statement of any payor's billing requirements or policies.

Payor agreements, fee schedules, and billing policies vary and are subject to change. Before submitting any claims related to maternity care services, including claims affected by the 2027 CPT code revisions, please consult the applicable payor agreements, coverage policies, and billing guidelines to confirm current requirements for their specific payor contracts.

Substrate makes no representation or warranty regarding the accuracy, completeness, or timeliness of the payor-specific information presented here. Providers are solely responsible for ensuring that all claims are submitted in accordance with applicable payor requirements, and Substrate assumes no liability for claim denials, underpayments, or other adverse outcomes arising from reliance on this information.